BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.4000
+0.0150 (+0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.3850
Open2.4000
Bid0.0000 x 2200
Ask0.0000 x 1800
Day's Range2.3300 - 2.4500
52 Week Range2.3200 - 9.9500
Volume696,163
Avg. Volume1,435,660
Market Cap252.859M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees options to purchase an aggregate of 103,000 shares of BioCryst common stock on September 30, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $2.87 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

  • GlobeNewswire

    U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

    With the exercise of the second option, BioCryst plans to deliver a total of 20,000 doses of RAPIVAB, which will add approximately $14 million of non-dilutive capital to the company, by the end of 2019. The RAPIVAB purchase by the HHS Office of the Assistant Secretary for Preparedness and Response will supply the Strategic National Stockpile, the nation’s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. “RAPIVAB is an important antiviral with proven benefits for influenza patients, and we appreciate the opportunity to fulfill these orders for HHS as they support patients and our national security,” said Jon Stonehouse, chief executive officer of BioCryst.

  • GlobeNewswire

    BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare.

  • GlobeNewswire

    BioCryst Appoints Helen Thackray, M.D., to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen.

  • GlobeNewswire

    BioCryst to Present at H.C. Wainwright Global Investment Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global.

  • GlobeNewswire

    BioCryst Reports Second Quarter 2019 Financial Results

    —New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019— —Data from ongoing Phase 1 trial of oral.

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees options to purchase an aggregate of 42,000 shares of BioCryst common stock on July 31, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.17 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

  • GlobeNewswire

    BioCryst to Report Second Quarter 2019 Financial Results on August 6

    RESEARCH TRIANGLE PARK, N.C., July 23, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial.

  • GlobeNewswire

    BioCryst Appoints Megan Sniecinski Chief Business Officer

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced the appointment of Megan Sniecinski as chief business officer. Ms. Sniecinski joins BioCryst from PTC Therapeutics, where she served as senior vice president of business operations and program management since June 2017. Over nearly five years at PTC, Ms. Sniecinski played a key role in supporting the diversified growth of PTC’s rare disease pipeline and transformation into a global, fully-integrated biopharmaceutical company.

  • GlobeNewswire

    Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has begun enrollment of a Phase 1 trial of BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, for the treatment of complement-mediated diseases. “An oral Factor D inhibitor would meet a significant unmet medical need for patients with many complement-mediated diseases. The preclinical profile of BCX9930 showed high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, so we look forward to seeing the clinical results from this Phase 1 trial,” said Dr. William Sheridan, chief medical officer of BioCryst.

  • GlobeNewswire

    BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., May 31, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies 2019 Healthcare.

  • GlobeNewswire

    BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial

    Fifty percent of patients receiving 150 mg BCX7353 in APeX-2 had a ≥ 70 percent reduction in their HAE attack rate compared to baseline, compared to 15 percent of placebo patients (p=0.002). In patients on the 150 mg dose with a baseline attack rate of

  • GlobeNewswire

    BioCryst to Present at Bank of America Merrill Lynch Health Care Conference

    RESEARCH TRIANGLE PARK, N.C., May 10, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch.

  • GlobeNewswire

    BioCryst Completes Phase 1 Clinical Trial of Galidesivir

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers.  In the trial, galidesivir was generally safe and well tolerated. This placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in four single-dose cohorts of 5mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg, with a total of 24 volunteers receiving galidesivir by IV infusion. Drug exposures (Cmax and AUC) at the highest dose were 20,500 ng/mL and 44,600 hr.ng/mL, similar to or greater than drug exposures needed in nonclinical galidesivir treatment experiments in Marburg virus disease and Yellow Fever.

  • GlobeNewswire

    BioCryst Reports First Quarter 2019 Financial Results

    —Phase 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Phase 3 ZENITH-2 trial.

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 141,224 shares of BioCryst common stock on April 30, 2019 and May 1, 2019, respectively, as inducements material to each employee entering into employment with BioCryst. The options have an exercise price of $7.43 and $7.28 per share, which is equal to the closing price of BioCryst common stock on each grant date. Each stock option vests in four equal annual installments beginning on the one-year anniversary of its grant date, in each case, subject to the new employee’s continued service with the company.

  • GlobeNewswire

    BioCryst to Report First Quarter 2019 Financial Results on May 8

    RESEARCH TRIANGLE PARK, N.C., April 24, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial.

  • GlobeNewswire

    Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics — Future Expectations, Projections Moving into 2019

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire

    BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results

    —APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Full ZENITH-1 results confirm.

  • GlobeNewswire

    BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, into Phase 1 clinical development in the second quarter of 2019 for the treatment of complement-mediated diseases. “Based on its outstanding preclinical profile, with high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, we are excited to advance oral BCX9930 into clinical development,” said Dr. William Sheridan, chief medical officer of BioCryst.

  • GlobeNewswire

    BioCryst to Present at Barclays Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare.